trontinemab

News

Alzheimer's biotech Korsana to go public via reverse merger

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.

News

Roche expands phase 3 plans for Alzheimer's drug

Roche has added a phase 3 trial of trontinemab, hoping to show it can delay or prevent progression to Alzheimer's symptoms in preclinical patients.

News

Graphical representation of Brainshuttle antibody at the blood-brain barrier

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.

Alzheimer's biotech Korsana to go public via reverse merger

Roche expands phase 3 plans for Alzheimer's drug

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Clock starts ticking on UK's single patient record plan

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks